BioAgilytix Team Q&A: Meet Eric Nesbit, Bioanalytical Project Manager/Scientist III
In this Q&A session we talk with Eric Nesbit, Bioanalytical Project Manager/Scientist III at BioAgilytix, to learn more about what led him to leave his…
Meet Jelle Hempenius, Business Development Director, Europe
Did you know that BioAgilytix’s ‘deep bench’ extends beyond those we have working in the lab? Many individuals in our operational departments, from business development…
510K Approved Assays vs. RUO Assays: Which Best Support Clinical Trial Biomarker Studies?
The answer to the question is “it depends”. Commonly a combination of 510K approved kits (in Europe known as assays that need to follow IVD-directive…
BioAgilytix Team Q&A: Meet Mike Losauro, Senior Business Development Director at BioAgilytix
Did you know that many of our team members have cross-functional background experience both in the lab and in customer-facing roles, making them uniquely equipped…
A History of Gene Therapy: Exploring Lessons Learned In Light of New Approvals
The FDA recently approved the first gene therapy for pediatric patients with SMA, signifying a major step forward for the therapeutic field as a whole.…
Key Takeaways from the 13th Annual WRIB, 2019
Last month at WRIB, our scientific team had the opportunity to participate in a number of discussions surrounding the latest topics of interest in biomarkers,…
The Fit for Flow Cytometry, Part 1: Ideal for Receptor Occupancy Assessment
Flow cytometry is an ideal platform for many applications involving the study of complex cell populations. In the first blog of our new “The Fit…
Key Takeaways from Oxford Global’s 14th Annual Biomarkers Congress
Couldn’t make the Oxford Global’s 14th Annual Biomarkers Congress? Read our recap of the key opportunities and challenges in biomarker development that scientists discussed.
Supporting a Gene Therapy Clinical Trial with Assay to Measure NAbs Against the AAV9 Serotype
Today we're featuring a case study on how BioAgilytix developed a cell-based assay to determine the prevalence of pre-existing antibodies against the AAV9 serotype in…
BioAgilytix Partnership Across Continents: Meet William Hunter and Todd Lester
With headquarters in the USA and Europe, effective team-wide communication is critical to our success. William Hunter, Director of BD & Global Key Accounts at…